Longeveron LLC (NASDAQ:LGVN) — Market Cap & Net Worth
Market Cap & Net Worth: Longeveron LLC (LGVN)
Longeveron LLC (NASDAQ:LGVN) has a market capitalization of $23.07 Million ($23.07 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #24666 globally and #5208 in its home market, demonstrating a 2.12% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Longeveron LLC's stock price $0.77 by its total outstanding shares 30148947 (30.15 Million). Review Longeveron LLC (LGVN) total liabilities to assess the company's total debt and financial obligations.
Longeveron LLC Market Cap History: 2021 to 2026
Longeveron LLC's market capitalization history from 2021 to 2026. Data shows change from $3.64 Billion to $23.21 Million (-57.46% CAGR).
Index Memberships
Longeveron LLC is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.00% | #704 of 976 |
|
NASDAQ Composite
IXIC
|
$41.27 Trillion | 0.00% | #2321 of 3165 |
Weight: Longeveron LLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Longeveron LLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Longeveron LLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
12.72x
Longeveron LLC's market cap is 12.72 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $3.64 Billion | $1.31 Million | -$17.05 Million | 2786.35x | N/A |
| 2022 | $970.80 Million | $1.22 Million | -$18.84 Million | 794.43x | N/A |
| 2023 | $410.03 Million | $709.00K | -$21.41 Million | 578.32x | N/A |
| 2024 | $52.16 Million | $2.39 Million | -$15.97 Million | 21.81x | N/A |
| 2025 | $15.26 Million | $1.20 Million | -$22.70 Million | 12.72x | N/A |
Competitor Companies of LGVN by Market Capitalization
Companies near Longeveron LLC in the global market cap rankings as of June 18, 2026.
Key companies related to Longeveron LLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Longeveron LLC Historical Marketcap From 2021 to 2026
Between 2021 and today, Longeveron LLC's market cap moved from $3.64 Billion to $ 23.21 Million, with a yearly change of -57.46%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $23.21 Million | +52.17% |
| 2025 | $15.26 Million | -70.75% |
| 2024 | $52.16 Million | -87.28% |
| 2023 | $410.03 Million | -57.76% |
| 2022 | $970.80 Million | -73.32% |
| 2021 | $3.64 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Longeveron LLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $23.07 Million USD |
| MoneyControl | $23.07 Million USD |
| MarketWatch | $23.07 Million USD |
| marketcap.company | $23.07 Million USD |
| Reuters | $23.07 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Longeveron LLC
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; com… Read more